Pallavi Madhiraju’s Post

1. Inquis Medical has secured $40 million in Series B financing, led by Marshall Wace, to advance its Aventus Thrombectomy System. 2. The financing round was oversubscribed, attracting participation from existing investors like ShangBay Capital and EnPointe Ventures. 3. Inquis Medical specializes in developing next-generation thrombectomy systems, with its flagship product featuring proprietary tissue-sensing technology. 4. The company received FDA 510(k) clearance earlier this year for its Aventus Thrombectomy System and is nearing completion of an FDA IDE clinical study for pulmonary embolism patients. 5. The Series B funding marks a significant milestone for Inquis Medical, enabling it to complete its pivotal trial and prepare for a commercial launch in 2025. 6. Venous thromboembolism affects up to 900,000 individuals in the U.S. annually, highlighting the need for efficient treatment solutions. 7. The investment confirms strong investor confidence in Inquis Medical’s technology and its potential to enhance patient care. 8. Andrew D. Goldberg from Marshall Wace has joined Inquis Medical’s Board of Directors as part of the financing arrangement.

🔔 Phagenesis Ltd Closes $42 Million Series D Financing 🔔 💰The UK based company has developed a neurostimulation system to treat swallowing dysfunction, has closed its Series D Financing. 👨🔬 Co-founded by Dr. Conor Mulrooney and Professor Shaheen Hamdy and led by CEO Reinhard Krickl the company offers innovative treatments for neurogenic dysphagia using pharyngeal electrical stimulation, PES. 💸 The round was led by EQT Life Sciences and Sectoral Asset Management with participation from new investors British Patient Capital, Northern Gritstone and Aphelion Capital. 📈 The company intends to use the funds to expand operations and development efforts. Recent approval of Phagenyx by the FDA in the US, the investment is primarily intended to support commercialisation in the US and deepen penetration in Europe. #funding #vc #vcfunding #vensight #insights #seriesd  #medtech #investment

I'm exposing myself in a couple of ways here - firstly because of my lack of knowledge of the 'eCOA' space - and secondly because of my use of personal medical information (TMI?) to illustrate some design goals for eCOA features in the early phase trial space. Skip to the end if you don't want to read about 'tubes' and 'plumbing'. https://lnkd.in/eZ-zaRQQ #esource #ecoa #earlyphasetrials

No matter the phase of your project, from pilot study to Phase IV post-market study, MERIT provides the expertise and technology to help you achieve your development goals. We seamlessly manage the imaging components of your trial, creating efficiencies for your #drugdevelopment. Check out summaries of two of our #ophthalmology case studies to learn more: https://lnkd.in/dPrVxdHZ #MERITCRO #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #casestudy #imagingsolutions

Today, CUREator deployed $5.84 million to five clinical-stage companies and $1.37 million to three pre-clinical stage companies through a ‘top-up’ round. 🧬Funding was made available from the Federal Government’s Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) grant. 🧬To date, CUREator-backed companies have secured $45.7m in private sector cash and in-kind support, from the $37.4m deployed by the program. 🧬CUREator delivers funding like an investor, in tranches based on milestone attainment. 🧬A novel program feature allows for the redistribution of funds from unmet milestones to supplement top-up funding rounds. 👇🏾Press release with awardees can be found here: https://rb.gy/h5ln44

Yesterday, we provided investors with a Q3 2024 update and year-to-date achievements, reaffirming our 2024 strategic priorities.  Our top focus remains preparing for commercialization of the ARC-EX System--pending FDA review--and we look forward to bringing ARC-EX to the Spinal Cord Injury (SCI) Community in the US later this year.*  Here are more ONWARD Medical accomplishments from the last several months:  ✅ Secured €50M in funding with cornerstone investment from Ottobock, now our largest strategic investor ✅ Signed an exclusive license for WIMAGINE® Brain Computer Interface (BCI) technology from Commissariat a l'Energie Atomique et aux Energies Alternatives to be commercialized with our ARC-BCI System  ✅ Announced former Medtronic President Rob ten Hoedt as incoming Board Chairman  ✅ ARC-EX System named a TIME Magazine Best Invention of 2024 ✅ Received $1.1 million grant to expand ARC-BCI feasibility research from the Christopher & Dana Reeve Foundation ✅ On track for first commercial launch in Q4 2024  Check out a recording of our Q3 Update Webcast at the link in comments. 🔗 As we approach the close of 2024, we are energized by the prospect of delivering our groundbreaking therapies to the SCI Community to advance our mission of restoring movement, function, and independence to people with SCI. ✨ #EmpoweringMovement #SCI #StrategicPriorities *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

No matter the phase of your project, from pilot study to Phase IV post-market study, MERIT provides the expertise and technology to help you achieve your development goals. We seamlessly manage the imaging components of your trial, creating efficiencies for your #drugdevelopment. Check out summaries of two of our #ophthalmology case studies to learn more: https://lnkd.in/dPrVxdHZ #MERITCRO #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #casestudy #imagingsolutions

Boston Scientific, a manufacturer of medical devices used in interventional medical specialties, completed the acquisition of Silk Road Medical, Inc., a medical device company that is focused on reducing the risk of stroke, for $1.26bn. "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach. The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes," Cat Jennings, Boston Scientific President. Boston Scientific (led by Mike Mahoney and Dan Brennan) was advised by Latham & Watkins (led by Julie Scallen and Ian Nussbaum). Silk Road Medical (led by Chas McKhann and Lucas Buchanan) was advised by Bank of America, Wilson Sonsini Goodrich & Rosati and Gilmartin Group LLC (led by Marissa Bych). Link to the article in the comments. #MergersAcquisitionsDivestitures #Medical #Equipment

Merit Medical Systems, Inc. has announced its latest strategic move by acquiring Cook Medical’s lead management device portfolio for $210 million. This significant acquisition underscores Merit’s commitment to expanding its offerings and enhancing its support for cardiac intervention patients. The deal is expected to close in Q4 2024, with Merit Medical leveraging cash reserves and long-term credit for the purchase. CEO Fred P. Lampropoulos highlighted that this acquisition aligns with Merit’s growth strategy and will enable the company to offer a more comprehensive range of solutions from diagnosis to post-procedure care. Cook Medical’s lead management portfolio, which has generated $37 million in revenue in 2023, is a valuable addition. The portfolio has a strong presence in the U.S. and EMEA regions. The transaction is pending antitrust approval but includes a transition agreement with Cook Medical for continued support over the next two years. In addition to this acquisition, Merit Medical recently acquired the rights to the EsophyX Z+ device from EndoGastric Solutions for $105 million. #MedTech #HealthcareInnovation #Acquisition #MeritMedical #InterventionalRadiology #CardiacCare

Boston Scientific's Latest Acquisition: A Game Changer in AFib Treatment Boston Scientific has just announced its continued M&A momentum with the acquisition of Cortex, a company specializing in diagnostic mapping technology for atrial fibrillation (AFib). This merger aims to enhance ablation procedure strategies, especially in complex AFib cases, leveraging Cortex's cutting-edge Optimap system. The deal, expected to close in the first half of 2025, brings Cortex's FDA-cleared Optimap technology under Boston Scientific's expansive electrophysiology portfolio. It will further bolster their position in the rapidly evolving field of AFib treatments. The recent billion-dollar acquisitions, including Silk Road Medical for $1.28 billion and the impending $3.7 billion Axonics deal, highlight Boston Scientific's aggressive strategy to consolidate its market leadership. Historically, Boston Scientific has been at the forefront of medical innovations, reminiscent of how visionary leaders like Dale Carnegie and Jim Collins describe strategic growth in their works. This purchase exemplifies a calculated move to incorporate advanced technology and enhance patient outcomes globally. Cortex's Optimap promises improved procedural efficacy, marking a significant shift towards more precise and effective AFib treatments. What do you think about this latest move by Boston Scientific? Let's discuss in the comments! #Medtech #AFib #Innovation